{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:25:17Z","timestamp":1768447517505,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R37 CA262557"],"award-info":[{"award-number":["R37 CA262557"]}]},{"name":"NIH","award":["R21 CA294042"],"award-info":[{"award-number":["R21 CA294042"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200046"],"award-info":[{"award-number":["RP200046"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11307-025-02054-9","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:17:10Z","timestamp":1758291430000},"page":"877-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Today\u2019s Research, Tomorrow\u2019s Practice \u2013 White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-4531","authenticated-orcid":false,"given":"Simone","family":"Krebs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan P.","family":"Coll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Charles","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"12","key":"2054_CR1","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A et al (2021) (177)lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"issue":"10446","key":"2054_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL et al (2024) [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403(10446):2807\u20132817","journal-title":"Lancet"},{"issue":"12","key":"2054_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"issue":"9","key":"2054_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J et al (2018) Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59(9):1415\u20131422","journal-title":"J Nucl Med"},{"key":"2054_CR5","unstructured":"Davis R, Foster C, Ganguly T, Hausner S, Kim E, Roncali E, Sutcliffe J (2023) First-in-human study of the theranostic pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in pancreatic adenocarcinoma. Journal of Nuclear Medicine 64(supplement 1):P1300-P."},{"issue":"2","key":"2054_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2967\/jnumed.124.268877","volume":"66","author":"E von Guggenberg","year":"2025","unstructured":"von Guggenberg E, di Santo G, Uprimny C, Bayerschmidt S, Warwitz B, H\u00f6rmann AA et al (2025) Safety, biodistribution, and radiation dosimetry of the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with advanced medullary thyroid cancer and other neuroendocrine tumors. J Nucl Med 66(2):257\u2013263","journal-title":"J Nucl Med"},{"key":"2054_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27185831","author":"KD Orcutt","year":"2022","unstructured":"Orcutt KD, Henry KE, Habjan C et al (2022) Dosimetry of [(212)Pb]VMT01, a MC1R-targeted alpha therapeutic compound, and effect of free (208)Tl on tissue absorbed doses. Molecules. https:\/\/doi.org\/10.3390\/molecules27185831","journal-title":"Molecules"},{"issue":"10","key":"2054_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM et al (2024) [(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol 25(10):1277\u20131287","journal-title":"Lancet Oncol"},{"issue":"8","key":"2054_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1470-2045(24)00249-3","volume":"25","author":"S Tendler","year":"2024","unstructured":"Tendler S, Dunphy MP, Agee M, O\u2019Donoghue J, Aly RG, Choudhury NJ et al (2024) Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial. Lancet Oncol 25(8):1015\u201324","journal-title":"Lancet Oncol"},{"issue":"10","key":"2054_CR10","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00259-023-06244-x","volume":"50","author":"S Boschi","year":"2023","unstructured":"Boschi S, Todde S (2023) Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain \u201cthe road taken.\u201d Eur J Nucl Med Mol Imaging 50(10):2921\u20132924","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2054_CR11","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M et al (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21(3):e146\u2013e156","journal-title":"Lancet Oncol"},{"issue":"4","key":"2054_CR12","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA et al (2021) Medical imaging and nuclear medicine: a lancet oncology commission. Lancet Oncol 22(4):e136\u2013e172","journal-title":"Lancet Oncol"},{"issue":"11","key":"2054_CR13","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","volume":"25","author":"M Abdel-Wahab","year":"2024","unstructured":"Abdel-Wahab M, Giammarile F, Carrara M, Paez D, Hricak H, Ayati N et al (2024) Radiotherapy and theranostics: a lancet oncology commission. Lancet Oncol 25(11):e545\u2013e580","journal-title":"Lancet Oncol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02054-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02054-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:37:57Z","timestamp":1768408677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02054-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2054"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02054-9","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"SK has a patent on THOR cell (tumor homing radio-emitting cell)\u2014\u201cTHOR\u201d C825 expressing immune cells and diagnostic uses thereof, and a patent on Anti-IL13ralpha2 antibody compositions and uses thereof issued. GP is an employee and shareholder of Evergreen Theragnostics, Inc.\u00a0MP is a coinventor on a U.S. patent covering PYLARIFY\u00ae and as such is entitled to a portion of licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. The authors report no other relevant conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}